GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rockwell Medical Inc (NAS:RMTI) » Definitions » Sloan Ratio %
中文

Rockwell Medical (Rockwell Medical) Sloan Ratio % : 7.70% (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Rockwell Medical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Rockwell Medical's Sloan Ratio for the quarter that ended in Dec. 2023 was 7.70%.

As of Dec. 2023, Rockwell Medical has a Sloan Ratio of 7.70%, indicating the company is in the safe zone and there is no funny business with accruals.


Rockwell Medical Sloan Ratio % Historical Data

The historical data trend for Rockwell Medical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rockwell Medical Sloan Ratio % Chart

Rockwell Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.79 -5.74 1.13 1.39 7.70

Rockwell Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 9.76 3.85 3.85 7.70

Competitive Comparison of Rockwell Medical's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Sloan Ratio % falls into.



Rockwell Medical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Rockwell Medical's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-8.439--9.412
--3.045)/52.173
=7.70%

Rockwell Medical's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-8.439--9.412
--3.045)/52.173
=7.70%

Rockwell Medical's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -1.75 (Mar. 2023 ) + -3.305 (Jun. 2023 ) + -1.872 (Sep. 2023 ) + -1.512 (Dec. 2023 ) = $-8.44 Mil.
Rockwell Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -3.876 (Mar. 2023 ) + -1.74 (Jun. 2023 ) + -3.753 (Sep. 2023 ) + -0.043 (Dec. 2023 ) = $-9.41 Mil.
Rockwell Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 5.302 (Mar. 2023 ) + -0.064 (Jun. 2023 ) + -10.291 (Sep. 2023 ) + 2.008 (Dec. 2023 ) = $-3.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rockwell Medical  (NAS:RMTI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Rockwell Medical has a Sloan Ratio of 7.70%, indicating the company is in the safe zone and there is no funny business with accruals.


Rockwell Medical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Rockwell Medical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rockwell Medical (Rockwell Medical) Business Description

Traded in Other Exchanges
Address
30142 S. Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. Rockwell Medical's mission is to provide dialysis clinics and patients with the highest quality products supported by the best customer service in the industry. It is focused on innovative, long-term growth strategies that enhance products, processes, and people, enabling the company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients.
Executives
Jesse Neri officer: SVP, FINANCE 851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Russell Skibsted officer: See Remarks 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Megan C. Timmins officer: SVP, General Counsel 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Mark Strobeck director, officer: President and CEO 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
David S. Richmond 10 percent owner, other: See Footnote 1 3568 WILDWOOD AVENUE, JACKSON MI 49202
Russell H Ellison director 270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025
Marc L Hoffman officer: Chief Medical Officer 30142 WIXOM ROAD, WIXOM MI 48393
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Richmond Brothers, Inc. 10 percent owner, other: See Footnote 1 7415 FOXWORTH COURT, JACKSON MI 49201
Stuart M Paul director, officer: Chief Executive Officer HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309
Angus W. Smith officer: Chief Financial Officer C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960